Menovex Medical Completes New Round of Financing to Accelerate Full-Chain Laser Medical Layout

VCBeat has learned at the earliest opportunity that,As a provider of multi-scenario laser medical system solutions and core components, MIL Medical Technology (Shenzhen) Co., Ltd. (“MIL MED TECH”) recently announced that it has completed a new round of financing. This round was led by Infinity Capital, with WinX Capital serving as the exclusive financial advisor.The completion of this financing round marks MIL MED TECH’s continued deepening of its presence across the entire upstream, midstream, and downstream laser medicine industry chain. The company will focus on the R&D and mass production of various specialized laser modules that meet clinical needs, continuously enhance its full-cycle, system-level laser medicine CDMO services for industry partners both domestically and internationally, and achieve the commercialization of innovative products while exploring emerging applications in laser medicine at home and abroad.

The funds raised in this round will be primarily allocated to MIL MED TECH’s product research and development, mass production, talent system development, and domestic and international commercial promotion. As the lead investor in this round, Infinity Capital will bring abundant industry resources and capital operation expertise to MIL MED TECH, facilitating the company’s leapfrog growth.

Zhang Shuai, Investment Director at Infinity Capitalstated: “Given the maturity of China’s domestic laser industry chain and advancements in clinical procedures both domestically and internationally, we believe this year is poised to be the ‘Year One for Chinese-made Medical Thulium Lasers.’ MIL MED TECH has established end-to-end capabilities spanning fundamental laser technology research, R&D and mass production of multiple laser models, and the development and regulatory approval of multidisciplinary clinical terminal devices, thereby beginning to demonstrate its value as a platform-type enterprise. As the medical laser market continues to deepen, the company holds significant value-creation potential across multiple disciplines, including urology, dentistry, dermatology, and ophthalmology. The founding team possesses profound insights and strategic vision in corporate positioning, technological implementation, and commercial strategy. We are delighted to partner with MIL MED TECH, leveraging this investment and introducing robust resources from Taizhou’s optoelectronics industry to help propel the company to new heights.”

WinX CapitalIt is indicated that, against the backdrop of severe homogenization in the medical device industry and strong national support for full-chain innovation, MIL MED TECH, as a leader in the laser medicine sector, is a typical representative of enterprises focused on “hard tech, chokepoint technologies, and domestic substitution.” By targeting key links in the industrial chain and pursuing more precise and efficient technological innovation, the company has firmly secured the initiative in China’s laser medicine development for domestic enterprises. Its business model—centered on building consensus, controlling upstream resources, selecting blue-ocean markets, and expanding internationally—is poised to break through the ceiling of traditional laser medicine and establish MIL MED TECH as a unicorn in the laser medicine field.

Since its establishment four years ago, MIL MED TECH has been committed to becoming a world-class innovative enterprise in laser medicine. The team masters cutting-edge international laser technologies and possesses unique technical advantages and extensive transferability in specialized laser therapeutic wavelengths. The company’s business spans the upstream laser sources, midstream CDMO services, and downstream laser medical devices within the laser healthcare industry. MIL MED TECH is dedicated to leveraging its laser technology platform to build a laser healthcare ecosystem characterized by high barriers to entry, strong growth potential, and substantial market size, with the goal of becoming a globally leading international brand in laser medicine.

The core founding members of MIL MED TECH are graduates of Tsinghua University, with over 80% of the management team hailing from leading domestic and international medical device R&D and manufacturing enterprises. The company has assembled a technological innovation team of nearly 100 professionals from the fields of clinical medicine, medical devices, and optoelectronics.

Promoting the cross-disciplinary integration of medicine and engineering, along with collaborative innovation across the supply chain, is a key factor in breaking through the “bottlenecks” hindering innovation in China’s medical device industry. Aligning with industry development trends, MIL MED TECH is building a laser medicine CDMO platform aimed at propelling China’s advanced laser-based minimally invasive medical technologies to the global forefront. Committed to achieving domestic substitution of core laser components, MIL MED TECH strives to help more medical device companies reduce overall costs, accelerate the translation of product technologies, and shorten time-to-market, thereby enabling clients to focus more intently on serving clinical needs.

The global market size for laser medical devices has exceeded RMB 100 billion, with the domestic market in China surpassing RMB 30 billion and gradually evolving into the world’s largest regional segment. As laser technology advances, new application areas continue to emerge, while laser devices in existing scenarios are being continuously upgraded. In fields such as medical aesthetics, urology, otolaryngology, and ophthalmology, lasers have become essential energy platforms. Furthermore, significant application potential exists in orthopedics, gynecology, neurosurgery, vascular surgery, and veterinary medicine. Chinese-made laser therapeutic devices are accelerating the industrialization of laser medicine in China by integrating business operations, building brands, and achieving comprehensive localization of components. Although China’s laser medical industry still faces challenges such as a high dependence on imports for high-end supply chain segments, as the world’s largest industrial laser market, China is poised to produce global leading enterprises in laser medicine with individual annual revenues exceeding RMB 5 billion. Leveraging its technological strengths, MIL MED TECH is committed to building global brand influence, product competitiveness, and channel capabilities, while providing better, more efficient, and more precise laser medical services to patients and healthcare providers worldwide, letting the light of technology safeguard public health.

Infinity Capital Management Co., Ltd. (hereinafter referred to as “Infinity Capital”) is the equity investment platform under Huafa Group, a leading state-owned enterprise in Zhuhai and one of China’s Top 500 Enterprises. It also serves as the core operational entity of Infinity Group, a renowned investment management firm originating from Israel. The company primarily manages onshore RMB funds and cross-border investment operations, with a presence in more than ten cities across China and abroad. It has established five major business segments: Healthcare, East China, South China, Southwest China, and Hong Kong & Overseas Regions. Infinity Capital has strategically focused on new energy, integrated circuits, healthcare and life sciences, advanced manufacturing, new materials, and TMT sectors. With assets under management exceeding RMB 10 billion, the firm has invested in over 130 projects, and dozens of its portfolio companies have successfully exited through IPOs on the Hong Kong Stock Exchange, A-share market, and U.S. stock markets, as well as via mergers and acquisitions.

WinX Capital is a leading investment bank in China’s healthcare sector, headquartered in Beijing and Shanghai, with coverage of over 3,000 active institutional investors and industrial groups. WinX Capital has received numerous accolades, including being ranked No. 1 Financial Advisor in the Healthcare Sector for 2022 and 2023 by First New Voice; Top 2 Best Financial Advisor in the Healthcare Sector for 2021–2022 by Qimingpian & New Voice Innovation Services; and Annual Healthcare Financial Advisor at VCBeat’s “Top 100 Future Healthcare Companies” from 2022 to 2024.